Terms: = Pancreatic cancer AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12 AND Treatment
35 results:
1. Immunization with a multi-antigen targeted DNA vaccine eliminates chemoresistant pancreatic cancer by disrupting tumor-stromal cell crosstalk.
Qin H; Chen J; Bouchekioua-Bouzaghou K; Meng YM; Griera JB; Jiang X; Kong X; Wang M; Xu Q; Wong PP
J Transl Med; 2023 Oct; 21(1):702. PubMed ID: 37814317
[TBL] [Abstract] [Full Text] [Related]
2. Cytomorphologic, immunophenotypical and molecular features of pancreatic acinar cell carcinoma.
Sun T; Gilani S; Jain D; Cai G
Diagn Cytopathol; 2023 Nov; 51(11):674-683. PubMed ID: 37469257
[TBL] [Abstract] [Full Text] [Related]
3. Precision medicine in gastroenteropancreatic neuroendocrine neoplasms: Where are we in 2023?
Fazio N; La Salvia A
Best Pract Res Clin Endocrinol Metab; 2023 Sep; 37(5):101794. PubMed ID: 37414651
[TBL] [Abstract] [Full Text] [Related]
4. FDA Approval Summary: Selpercatinib for the treatment of Advanced ret Fusion-Positive Solid Tumors.
Duke ES; Bradford D; Marcovitz M; Amatya AK; Mishra-Kalyani PS; Nguyen E; Price LSL; Fourie Zirkelbach J; Li Y; Bi Y; Kraft J; Dorff SE; Scepura B; Stephenson M; Ojofeitimi I; Nair A; Han Y; Tezak Z; Lemery SJ; Pazdur R; Larkins E; Singh H
Clin Cancer Res; 2023 Sep; 29(18):3573-3578. PubMed ID: 37265412
[TBL] [Abstract] [Full Text] [Related]
5. Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities.
Zhang L; Feng Q; Wang J; Tan Z; Li Q; Ge M
Biochim Biophys Acta Rev Cancer; 2023 Jul; 1878(4):188928. PubMed ID: 37257629
[TBL] [Abstract] [Full Text] [Related]
6. Advances in the treatment of Gastroenteropancreatic Neuroendocrine Carcinomas: Are we Moving Forward?
Garcia-Carbonero R; Anton-Pascual B; Modrego A; Del Carmen Riesco-Martinez M; Lens-Pardo A; Carretero-Puche C; Rubio-Cuesta B; Soldevilla B
Endocr Rev; 2023 Jul; 44(4):724-736. PubMed ID: 36879384
[TBL] [Abstract] [Full Text] [Related]
7. ret c.1901G>A and Novel SLC12A3 Mutations in Familial Pheochromocytomas.
Zhao L; Yang KQ; Fan P; Gong DX; Zhang L; Lu YT; Meng X; Zhou XL
Genes (Basel); 2022 May; 13(5):. PubMed ID: 35627249
[TBL] [Abstract] [Full Text] [Related]
8. Recent Advances in Epidermal Growth Factor Receptor Inhibitors (EGFRIs) and their Role in the treatment of cancer: A Review.
Unnisa A; Chettupalli AK; Hussain T; Kamal MA
Anticancer Agents Med Chem; 2022; 22(20):3370-3381. PubMed ID: 35400324
[TBL] [Abstract] [Full Text] [Related]
9. Anticancer drug resistance: An update and perspective.
Nussinov R; Tsai CJ; Jang H
Drug Resist Updat; 2021 Dec; 59():100796. PubMed ID: 34953682
[TBL] [Abstract] [Full Text] [Related]
10. Identification of ret fusions in a Chinese multicancer retrospective analysis by next-generation sequencing.
Shi M; Wang W; Zhang J; Li B; Lv D; Wang D; Wang S; Cheng D; Ma T
Cancer Sci; 2022 Jan; 113(1):308-318. PubMed ID: 34710947
[TBL] [Abstract] [Full Text] [Related]
11. Establishment and characterization of NCC-MLPS1-C1: a novel patient-derived cell line of myxoid liposarcoma.
Noguchi R; Yoshimatsu Y; Sei A; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
Hum Cell; 2021 Mar; 34(2):667-674. PubMed ID: 33146842
[TBL] [Abstract] [Full Text] [Related]
12. ret isoforms contribute differentially to invasive processes in pancreatic ductal adenocarcinoma.
Lian EY; Hyndman BD; Moodley S; Maritan SM; Mulligan LM
Oncogene; 2020 Oct; 39(41):6493-6510. PubMed ID: 32884116
[TBL] [Abstract] [Full Text] [Related]
13. ret fusions in solid tumors.
Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
[TBL] [Abstract] [Full Text] [Related]
14. ret, a targetable driver of pancreatic adenocarcinoma.
Amit M; Na'ara S; Fridman E; Vladovski E; Wasserman T; Milman N; Gil Z
Int J Cancer; 2019 Jun; 144(12):3014-3022. PubMed ID: 30515799
[TBL] [Abstract] [Full Text] [Related]
15. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review).
Katoh M
Int J Oncol; 2017 Nov; 51(5):1357-1369. PubMed ID: 29048660
[TBL] [Abstract] [Full Text] [Related]
16. Sunitinib in the treatment of Thyroid cancer.
Ferrari SM; Centanni M; Virili C; Miccoli M; Ferrari P; Ruffilli I; Ragusa F; Antonelli A; Fallahi P
Curr Med Chem; 2019; 26(6):963-972. PubMed ID: 28990511
[TBL] [Abstract] [Full Text] [Related]
17. Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.
Middleton G; Palmer DH; Greenhalf W; Ghaneh P; Jackson R; Cox T; Evans A; Shaw VE; Wadsley J; Valle JW; Propper D; Wasan H; Falk S; Cunningham D; Coxon F; Ross P; Madhusudan S; Wadd N; Corrie P; Hickish T; Costello E; Campbell F; Rawcliffe C; Neoptolemos JP
Lancet Oncol; 2017 Apr; 18(4):486-499. PubMed ID: 28259610
[TBL] [Abstract] [Full Text] [Related]
18. Antiangiogenic Therapy in pancreatic Neuroendocrine Tumors.
Capozzi M; VON Arx C; DE Divitiis C; Ottaiano A; Tatangelo F; Romano GM; Tafuto S;
Anticancer Res; 2016 Oct; 36(10):5025-5030. PubMed ID: 27798861
[TBL] [Abstract] [Full Text] [Related]
19. The molecular mechanisms of a novel multi-kinase inhibitor ZLJ33 in suppressing pancreatic cancer growth.
Li Y; Tang K; Zhang L; Li C; Niu F; Zhou W; Yang H; Feng Z; Chen X
Cancer Lett; 2015 Jan; 356(2 Pt B):392-403. PubMed ID: 25301453
[TBL] [Abstract] [Full Text] [Related]
20. Cabozantinib: a MET, ret, and VEGFR2 tyrosine kinase inhibitor.
Grüllich C
Recent Results Cancer Res; 2014; 201():207-14. PubMed ID: 24756794
[TBL] [Abstract] [Full Text] [Related]
[Next]
